Drug use and hepatitis infection are widespread in Irish prisons

July 06, 2000

Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey

Drug use and infection with hepatitis C are endemic among Irish prisoners, stressing the need for scrutiny and improvement of the Irish prison healthcare system, according to a study in this week's BMJ.

Researchers in the Republic of Ireland surveyed over 1,300 prisoners aged between 16 and 67 years of age who were considered to be at medium or high risk for blood borne viral infections. The authors found 9% of prisoners had evidence of current or past infection with hepatitis B, 37% with hepatitis C and 2% with HIV. Drug use is the most important predictor of infection, say the authors. Prisoners who reported injecting drugs were 81 times more likely to be positive for hepatitis C and 22 times more likely to be positive for hepatitis B than non-drug using prisoners. Alarmingly, the authors also found that 21% of prisoners reported that they had started to inject drugs while in prison and 71% reported sharing needles in prison - clearly increasing their risk of infection even further.

In Ireland, as elsewhere, injecting drug use in prison is here to stay, say the authors. Despite improvement in community drug treatment services, the Irish prison healthcare system has not kept pace with the high rates of injecting drug use and sharing of needles within Irish prisons. They call on policy makers, researchers and clinicians working in prisons to implement measures to ensure that being in prison does not add to the health risks of this already disadvantaged population.
-end-
Contacts:

Fiona Bradley, Lecturer in General Practice, Department of Community Health and General Practice, Trinity College, Dublin 2, Republic of Ireland. Email: fbradley@tcd.ie

Lelia Thornton, Specialist in Public Health Medicine, Eastern Regional Health Authority and Lecturer in Public Health, Department of Community Health and General Practice, Trinity College, Dublin 2, Republic of Ireland. Email: thornton@ehbph.iol.ie

BMJ

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.